FDA grants fast track designation to diagnostic agent for clear cell renal cell carcinomaByHannah ClarkeNovember 17th 2025
Community practice experience shows early efficacy, favorable safety with nadofarageneByJohn Eifler, MDNovember 14th 2025
Dual targeting of PAM and AR pathways yields encouraging results in mCRPCByAlice Bernard-Tessier, MDNovember 13th 2025